Search
Lifecore Biomedical Inc
LFCRAdd to Watchlist
5.090USD
-0.180-3.42%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
190.76MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Lifecore Biomedical Inc is 8.00, ranking 56 out of 157 in the Pharmaceuticals industry. The average price target is 8.75, with a high of 10.00 and a low of 7.50.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
6.833
Target Price
+29.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Lifecore Biomedical Inc
LFCR
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lifecore Biomedical Inc's expected revenue for the next quarter?
Lifecore Biomedical Inc's expected revenue is 26.50M.
What is Lifecore Biomedical Inc's price target?
Analysts forecast that Lifecore Biomedical Inc's price target is USD 8.75, with the highest forecast at USD 10.00 and the lowest forecast at USD 7.50.
How have Lifecore Biomedical IncLFCR's recent earnings per share performed?
The market expectation was USD -0.43, while Lifecore Biomedical IncLFCR's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.24.
What is the analyst rating for Lifecore Biomedical Inc?
Based on the ratings of Lifecore Biomedical Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.